Investor Brand Network

The White House hasn’t disclosed whether President Joseph Biden backs the U.S. Department of Justice’s (DOJ) proposal to reclassify cannabis after a review he initiated. During a conversation with Karine Jean-Pierre, the White House press secretary, reporters asked questions regarding the president’s stance on the DOJ’s proposal to shift marijuana from Schedule I to III.

Jean Pierre responded by noting that Biden’s administration would let the review... (continue reading...)

The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for the psychedelics sector and one of more than 60 brands powered by IBN (“InvestorBrandNetwork”), will be the official media sponsor for this month’s conference. The fourth annual Psychedelic Therapeutics and Drug Development Conference is scheduled for May 23–24, 2024, in Boston. Hosted by Arrowhead SciTech Conferences &... (continue reading...)

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a leading green ammonia company, is reporting an update on several notable actions, including the closing of the first tranche of a private placement, Manitoba on-farm installations, the appointment of Michael Heslin as the company’s new director of sales, and significant progress in government and stakeholder relations activities at both federal and provincial levels focused on building state-of-the-art mass-production... (continue reading...)

Bravo (OTC: BRVO) is implementing a rapid-growth strategy that builds on a strong, solid foundation of streaming media and technology. “The company recently acquired the TVee NOW(TM) streaming platform, fulfilling the terms of an asset purchase agreement signed earlier this year with Streaming TVEE, Inc… Bravo Multinational recently hired Richard (‘Rick’) Jones of Jones & Haley, P.C. as a legal advisor to assist the company with its plans to uplist onto a... (continue reading...)

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of... (continue reading...)